HALOZYME THERAPEUTICS, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-12-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-06-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-03-31 was $150.08M.
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for fiscal 2023 was $150.08M.
- HALOZYME THERAPEUTICS, INC. treasury stock, value, acquired, cost method for fiscal 2020 was $150.00M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-20 | $150.08M 10-K · filed 2024-02-20 |
| 2023-09-30 | $0.00 10-K · filed 2024-02-20 | $150.08M derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-06-30 | $0.00 10-K · filed 2024-02-20 | $350.08M derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-03-31 | $150.08M 10-K · filed 2024-02-20 | $350.08M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-21 | $200.00M 10-Q · filed 2024-05-07 |
| 2022-09-30 | $200.00M 10-K · filed 2023-02-21 | $210.32M derived: sum of 4 quarters · filed 2023-02-21 |
| 2022-06-30 | $0.00 10-K · filed 2023-02-21 | $75.04M derived: sum of 4 quarters · filed 2023-02-21 |
| 2022-03-31 | $0.00 10-K · filed 2023-02-21 | $123.88M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-12-31 | $10.32M 10-K · filed 2022-02-22 | $150.00M 10-Q · filed 2024-05-07 |
| 2021-09-30 | $64.72M 10-K · filed 2022-02-22 | $301.20M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $48.84M 10-K · filed 2022-02-22 | $295.39M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $150.00M 10-Q · filed 2022-08-09 | $248.54M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $37.65M 10-K · filed 2021-02-23 | $150.00M 10-K · filed 2023-02-21 |
| 2020-09-30 | $58.90M 10-K · filed 2021-02-23 | |
| 2020-06-30 | $2.00M 10-K · filed 2021-02-23 | |
| 2020-03-31 | $51.57M 10-K · filed 2021-02-23 | |
| 2019-12-31 | $200.00M 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |